GSK unites with 23andMe amid R&D revamp

GSK revealed its new approach to research and development (R&D) earlier this week, including a partnership with DNA testing company 23andMe.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

23andMe’s ‘designer baby’ patent sparks controversy

8 October 2013 Personal genomics company 23andMe has received a patent covering its Family Traits Inheritance Calculator tool that lets prospective parents see what traits their children may inherit.

Americas

FDA orders 23andMe to cease PGS sales

26 November 2013 The US Food and Drug Administration has told genetics company 23andMe to stop selling its Personal Genome Service product immediately.

Americas

GSK unites with CRISPR pioneer Doudna

14 June 2019 British-based pharmaceutical company GSK has entered into a five-year collaboration with the University of California to explore how gene mutations cause disease and accelerate drug discovery.

More on this story

Americas

23andMe’s ‘designer baby’ patent sparks controversy

8 October 2013 Personal genomics company 23andMe has received a patent covering its Family Traits Inheritance Calculator tool that lets prospective parents see what traits their children may inherit.

Americas

FDA orders 23andMe to cease PGS sales

26 November 2013 The US Food and Drug Administration has told genetics company 23andMe to stop selling its Personal Genome Service product immediately.

Americas

GSK unites with CRISPR pioneer Doudna

More on this story

Americas

23andMe’s ‘designer baby’ patent sparks controversy

8 October 2013 Personal genomics company 23andMe has received a patent covering its Family Traits Inheritance Calculator tool that lets prospective parents see what traits their children may inherit.

Americas

FDA orders 23andMe to cease PGS sales

26 November 2013 The US Food and Drug Administration has told genetics company 23andMe to stop selling its Personal Genome Service product immediately.

Americas

GSK unites with CRISPR pioneer Doudna